In Phase I/II clinical trials, the efficacy of durvalumab in patients with NSCLC was assessed, having previously determined the level of PD-L1 expression in tumor cells, considering the result to be positive at a PD-L1 expression level of ≥25%. This evidence concerns the gene CD274 and neoplasm.